PMID- 28223087
OWN - NLM
STAT- MEDLINE
DCOM- 20180417
LR  - 20180417
IS  - 1878-7533 (Electronic)
IS  - 1550-7289 (Linking)
VI  - 13
IP  - 6
DP  - 2017 Jun
TI  - Do sleeve gastrectomy and gastric bypass influence treatment with proton pump 
      inhibitors 4 years after surgery? A nationwide cohort.
PG  - 951-959
LID - S1550-7289(16)30877-2 [pii]
LID - 10.1016/j.soard.2016.12.013 [doi]
AB  - BACKGROUND: Gastroesophageal reflux disease (GERD) is a common obesity-related 
      co-morbidity that routinely is treated by continuous proton pump inhibitor (PPI) 
      therapy. A number of concerns have been raised regarding the risk of de novo GERD 
      or exacerbation of preexisting GERD after sleeve gastrectomy (SG). OBJECTIVE: To 
      assess PPI use at 4 years after bariatric surgery. SETTING: French National 
      Health Insurance. METHODS: Data were extracted from the French National Health 
      Insurance database. All adult obese patients who had undergone gastric bypass 
      (GBP) (n = 8250) or SG (n = 11,923) in 2011 in France were included. Patients 
      were considered to be on continuous PPI therapy when PPIs were dispensed>/=6 times 
      per year. Logistic regression models were used to compute odds ratios for 
      potential risk factors for PPI reimbursement 4 years after surgery. RESULTS: 
      Overall, continuous use of PPIs increased from baseline to 4 years after SG and 
      GBP, from 10.9% to 26.5% (P<.001) and from 11.4% to 21.9% (P<.001), respectively. 
      Among patients who underwent PPI therapy before surgery, those who had undergone 
      SG were more likely to continue PPI therapy 4 years after surgery compared with 
      those who underwent GBP (72.7% versus 59.2%; P<.001). In multivariate analyses, 
      the major risk factors for persistent continuous PPI treatment 4 years after 
      surgery were the following: SG (odds ratio [OR] = 1.87; 95% confidence interval 
      [CI] 1.55-2.25), higher body mass index (OR 1.85; 95% CI 1.35-2.5), and 
      preoperative antidepressant treatment (OR 1.89; 95% CI 1.56-2.29). CONCLUSION: At 
      a nationwide scale, continuous PPI treatment is used by 1 of 10 obese patients 
      before bariatric surgery, but by 1 of 4 patients 4 years after surgery. SG 
      compared with GBP, higher body mass index, and other coexisting conditions are 
      the 3 major risk factors for medium-term continuous PPI therapy.
CI  - Copyright (c) 2017 American Society for Bariatric Surgery. Published by Elsevier 
      Inc. All rights reserved.
FAU - Thereaux, Jeremie
AU  - Thereaux J
AD  - Department of Statistics, Caisse Nationale d'Assurance Maladie des Travailleurs 
      Salaries, Paris, France; Department of General, Digestive and Metabolic Surgery, 
      La Cavale Blanche University Hospital, Brest, France; University of Bretagne 
      Occidentale, EA 3878 Brest, France.
FAU - Lesuffleur, Thomas
AU  - Lesuffleur T
AD  - Department of Statistics, Caisse Nationale d'Assurance Maladie des Travailleurs 
      Salaries, Paris, France.
FAU - Czernichow, Sebastien
AU  - Czernichow S
AD  - Department of Nutrition, Hopital Europeen-Georges Pompidou, Assistance 
      Publique-Hopitaux de Paris, Paris, France; Centre for Epidemiological Cohort in 
      Population, Villejuif, France.
FAU - Basdevant, Arnaud
AU  - Basdevant A
AD  - Institute of Cardiometabolism and Nutrition, Heart and Nutrition Department, 
      Paris, France.
FAU - Msika, Simon
AU  - Msika S
AD  - Department of General, Digestive and Metabolic Surgery, Louis Mourier Hospital, 
      Assistance Publique-Hopitaux de Paris, Colombes, France.
FAU - Nocca, David
AU  - Nocca D
AD  - Department of Digestive Surgery, CHU de Montpellier, Montpellier, France.
FAU - Millat, Bertrand
AU  - Millat B
AD  - Department of Statistics, Caisse Nationale d'Assurance Maladie des Travailleurs 
      Salaries, Paris, France.
FAU - Fagot-Campagna, Anne
AU  - Fagot-Campagna A
AD  - Department of Statistics, Caisse Nationale d'Assurance Maladie des Travailleurs 
      Salaries, Paris, France. Electronic address: anne.fagot@cnamts.fr.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20161223
PL  - United States
TA  - Surg Obes Relat Dis
JT  - Surgery for obesity and related diseases : official journal of the American 
      Society for Bariatric Surgery
JID - 101233161
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
CIN - Surg Obes Relat Dis. 2017 Jun;13(6):960-961. PMID: 28411020
MH  - Adult
MH  - Aged
MH  - Bariatric Surgery/*methods
MH  - Female
MH  - Gastrectomy/*methods
MH  - Gastric Bypass/*methods
MH  - Gastroesophageal Reflux/*drug therapy/etiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Obesity, Morbid/complications/surgery
MH  - Postoperative Complications/drug therapy/etiology
MH  - Proton Pump Inhibitors/*therapeutic use
MH  - Young Adult
OTO - NOTNLM
OT  - Gastric bypass
OT  - Gastroesophageal reflux disease
OT  - Proton pump inhibitor
OT  - Sleeve gastrectomy
EDAT- 2017/02/23 06:00
MHDA- 2018/04/18 06:00
CRDT- 2017/02/23 06:00
PHST- 2016/10/24 00:00 [received]
PHST- 2016/12/05 00:00 [revised]
PHST- 2016/12/14 00:00 [accepted]
PHST- 2017/02/23 06:00 [pubmed]
PHST- 2018/04/18 06:00 [medline]
PHST- 2017/02/23 06:00 [entrez]
AID - S1550-7289(16)30877-2 [pii]
AID - 10.1016/j.soard.2016.12.013 [doi]
PST - ppublish
SO  - Surg Obes Relat Dis. 2017 Jun;13(6):951-959. doi: 10.1016/j.soard.2016.12.013. 
      Epub 2016 Dec 23.